Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying > 1,000 CTG Repeats from the Human DM1 Locus

Archive ouverte

Huguet, Aline | Medja, Fadia | Nicole, Annie | Vignaud, Alban | Guiraud-Dogan, Celine | Ferry, Arnaud | Decostre, Valerie | Hogrel, Jean-Yves | Metzger, Friedrich | Hoeflich, Andreas | Baraibar, Martin | Gomes-Pereira, Mario | Puymirat, Jack | Bassez, Guillaume | Furling, Denis | Munnich, Arnold | Gourdon, Genevieve

Edité par CCSD ; Public Library of Science -

International audience. Myotonic dystrophy type 1 (DM1) is caused by an unstable CTG repeat expansion in the 39UTR of the DM protein kinase (DMPK) gene. DMPK transcripts carrying CUG expansions form nuclear foci and affect splicing regulation of various RNA transcripts. Furthermore, bidirectional transcription over the DMPK gene and non-conventional RNA translation of repeated transcripts have been described in DM1. It is clear now that this disease may involve multiple pathogenic pathways including changes in gene expression, RNA stability and splicing regulation, protein translation, and micro-RNA metabolism. We previously generated transgenic mice with 45-kb of the DM1 locus and >300 CTG repeats (DM300 mice). After successive breeding and a high level of CTG repeat instability, we obtained transgenic mice carrying >1,000 CTG (DMSXL mice). Here we described for the first time the expression pattern of the DMPK sense transcripts in DMSXL and human tissues. Interestingly, we also demonstrate that DMPK antisense transcripts are expressed in various DMSXL and human tissues, and that both sense and antisense transcripts accumulate in independent nuclear foci that do not co-localize together. Molecular features of DM1-associated RNA toxicity in DMSXL mice (such as foci accumulation and mild missplicing), were associated with high mortality, growth retardation, and muscle defects (abnormal histopathology, reduced muscle strength, and lower motor performances). We have found that lower levels of IGFBP-3 may contribute to DMSXL growth retardation, while increased proteasome activity may affect muscle function. These data demonstrate that the human DM1 locus carrying very large expansions induced a variety of molecular and physiological defects in transgenic mice, reflecting DM1 to a certain extent. As a result, DMSXL mice provide an animal tool to decipher various aspects of the disease mechanisms. In addition, these mice can be used to test the preclinical impact of systemic therapeutic strategies on molecular and physiological phenotypes.

Consulter en ligne

Suggestions

Du même auteur

Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour.. Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour.: Synaptic dysfunction in myotonic dystrophy

Archive ouverte | Hernández-Hernández, Oscar | CCSD

International audience. Myotonic dystrophy type 1 is a complex multisystemic inherited disorder, which displays multiple debilitating neurological manifestations. Despite recent progress in the understanding of the ...

Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice

Archive ouverte | Klein, Arnaud, F | CCSD

International audience. Antisense oligonucleotides (ASOs) targeting pathologic RNAs have shown promising therapeutic corrections for many genetic diseases including myotonic dystrophy (DM1). Thus, ASO strategies for...

Enhanced systemic delivery of antisense oligonucleotides using cell-penetrating peptide to reverse RNA toxicity in DM1

Archive ouverte | Klein, Arnaud | CCSD

International audience. "IntroductionAntisense oligonucleotides (AON) targeting expanded-CUG transcripts to either degrade the pathogenic RNAs or interfere with abnormal binding/sequestration of RNA-binding proteins...

Chargement des enrichissements...